Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Novavax Inc (NASDAQ:NVAX)

6.09
Delayed Data
As of 3:59pm ET
 +0.23 / +3.92%
Today’s Change
4.08
Today|||52-Week Range
15.01
-27.41%
Year-to-Date
Better Buy: Novavax, Inc. vs. Pfizer Inc.
May 30 / MotleyFool.com - Paid Partner Content
Billionaire George Soros' Fund Bought These Stocks: Should You?
May 21 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close5.86
Today’s open5.98
Day’s range5.93 - 6.29
Volume9,038,046
Average volume (3 months)6,972,814
Market cap$1.6B
Dividend yield--
Data as of 3:59pm ET, 05/31/2016

Growth & Valuation

Earnings growth (last year)-62.16%
Earnings growth (this year)-59.85%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)+18.24%
P/E ratioNM
Price/Sales60.70
Price/Book5.41

Competitors

 Today’s
change
Today’s
% change
BLUEbluebird bio Inc+1.10+2.49%
RDUSRadius Health Inc+1.21+3.45%
OPHTOphthotech Corp+2.56+5.01%
HALOHalozyme Therapeutic...+0.06+0.60%
Data as of 3:59pm ET, 05/31/2016

Financials

Next reporting dateAugust 3, 2016
EPS forecast (this quarter)-$0.25
Annual revenue (last year)$36.3M
Annual profit (last year)-$156.9M
Net profit margin-432.93%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Stanley C. Erck
Senior Vice President-
Quality Operations
Robert Darius
Corporate headquarters
Gaithersburg, Maryland

Forecasts

Partner Offers

Search for Jobs